{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:59:34Z","timestamp":1784091574274,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The University of Castilla-La Mancha received funds from Amryt Pharmaceuticals DAC","award":["The University of Castilla-La Mancha received funds from Amryt Pharmaceuticals DAC"],"award-info":[{"award-number":["The University of Castilla-La Mancha received funds from Amryt Pharmaceuticals DAC"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>. Epidermolysis bullosa (EB) is a rare genetic skin disorder characterized by fragility of skin with appearance of acute and chronic wounds. The aim of this study was to determine the economic burden and the health-related quality of life (HRQoL) of patients with epidermolysis bullosa (EB) in Spain from a societal perspective.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>. We conducted a cross-sectional, retrospective study including 62 patients with EB (62% dystrophic, 9.6% junctional, 3.2% Kindler syndrome, and 26% with simplex EB). Data were collected from questionnaires completed by patients or their caregivers. The costs were estimated, including not only direct healthcare costs but also direct non-healthcare costs and productivity losses. We compared severe EB (Dystrophic, Junctional EB and Kindler syndrome) to non-severe EB (simplex EB) using as reference year 2022. HRQoL was measured by generic (EQ-5D) and specific (QoLEB) questionnaires.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The average annual cost for an EB patient was \u20ac31,352. Direct healthcare costs represented 17.2% of the total cost, direct non-healthcare costs (mainly informal care costs) 71.3% and productivity losses 11.5% of the total cost. Participants in the severe EB group had a slightly higher average cost than participants in the non-severe EB group (\u20ac31,706 vs. \u20ac30,337). Direct healthcare costs and non-healthcare costs were higher in the severe EB group (\u20ac6,205 vs. \u20ac3,024 and \u20ac23,148 vs. \u20ac20,113) while productivity losses were higher in the non-severe EB group (\u20ac7,200 vs. \u20ac2,353). The mean utility index score, where the maximum value possible is one, was 0.45 for patients with severe EB (0.76 for their caregivers) and 0.62 for those with non-severe EB (0.77 for their caregivers).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>. The social economic burden of EB, resulting from the high direct non-healthcare cost of informal care, and from the loss of productivity, accentuates the importance of not restricting cost analysis to direct healthcare costs. This substantiates that EB, particularly severe EB represents a significant hidden cost that should be revealed to society and should be considered in the support programmes for people who suffer from this disease, and in the economic evaluation of new treatments.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-024-03328-1","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T12:01:32Z","timestamp":1727092892000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Economic burden and health-related quality of life in patients with epidermolysis bullosa in Spain"],"prefix":"10.1186","volume":"19","author":[{"given":"Isaac","family":"Aranda-Reneo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Oliva-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7224-2189","authenticated-orcid":false,"given":"Luz Mar\u00eda","family":"Pe\u00f1a-Longobardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro Rafael","family":"Villar-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"L\u00f3pez-Bastida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"issue":"4","key":"3328_CR1","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/bjd.18921","volume":"183","author":"C Has","year":"2020","unstructured":"Has C, Bauer JW, Bodemer C, Bolling MC, Bruckner-Tuderman L, Diem A, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020;183(4):614\u201327.","journal-title":"Br J Dermatol"},{"issue":"6","key":"3328_CR2","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jaad.2008.02.004","volume":"58","author":"JD Fine","year":"2008","unstructured":"Fine JD, Eady RA, Bauer EA, Bauer JW, Bruckner-Tuderman L, Heagerty A, et al. The classification of inherited epidermolysis bullosa (EB): report of the Third International Consensus Meeting on diagnosis and classification of EB. J Am Acad Dermatol. 2008;58(6):931\u201350.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"3328_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10880-010-9205-4","volume":"17","author":"F Margari","year":"2010","unstructured":"Margari F, Lecce PA, Santamato W, Ventura P, Sportelli N, Annicchiarico G, et al. Psychiatric symptoms and quality of life in patients affected by epidermolysis bullosa. J Clin Psychol Med Settings. 2010;17(4):333\u20139.","journal-title":"J Clin Psychol Med Settings"},{"issue":"3","key":"3328_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1586\/erp.10.28","volume":"10","author":"C Pagliarello","year":"2010","unstructured":"Pagliarello C, Tabolli S. Factors affecting quality of life in Epidermolysis Bullosa. Expert Rev Pharmacoecon Outcomes Res. 2010;10(3):329\u201338.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"3328_CR5","unstructured":"Orphanet Report Series. Prevalence of rare diseases: Bibliographic data2013; June."},{"issue":"11","key":"3328_CR6","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/jamadermatol.2016.2473","volume":"152","author":"JD Fine","year":"2016","unstructured":"Fine JD. Epidemiology of inherited Epidermolysis Bullosa based on incidence and prevalence estimates from the National Epidermolysis Bullosa Registry. JAMA Dermatol. 2016;152(11):1231\u20138.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"3328_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2217\/rme.13.33","volume":"8","author":"S Carulli","year":"2013","unstructured":"Carulli S, Contin R, De Rosa L, Pellegrini G, De Luca M. The long and winding road that leads to a cure for epidermolysis bullosa. Regen Med. 2013;8(4):467\u201381.","journal-title":"Regen Med"},{"key":"3328_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000350009","volume":"44","author":"JD Fine","year":"2013","unstructured":"Fine JD. Cumulative life course impairment by Epidermolysis Bullosa. Curr Probl Dermatol. 2013;44:91\u2013101.","journal-title":"Curr Probl Dermatol"},{"issue":"5","key":"3328_CR9","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/j.1365-2133.2009.09041.x","volume":"160","author":"C Moss","year":"2009","unstructured":"Moss C, Wong A, Davies P. The Birmingham Epidermolysis Bullosa Severity score: development and validation. Br J Dermatol. 2009;160(5):1057\u201365.","journal-title":"Br J Dermatol"},{"key":"3328_CR10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12916-014-0178-2","volume":"12","author":"KR Goldschneider","year":"2014","unstructured":"Goldschneider KR, Good J, Harrop E, Liossi C, Lynch-Jordan A, Martinez AE, et al. Pain care for patients with epidermolysis bullosa: best care practice guidelines. BMC Med. 2014;12:178.","journal-title":"BMC Med"},{"issue":"1","key":"3328_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13023-019-1086-5","volume":"14","author":"K Martin","year":"2019","unstructured":"Martin K, Geuens S, Asche JK, Bodan R, Browne F, Downe A, et al. Psychosocial recommendations for the care of children and adults with epidermolysis bullosa and their family: evidence based guidelines. Orphanet J Rare Dis. 2019;14(1):133.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"3328_CR12","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/pde.12262","volume":"31","author":"EA Eismann","year":"2014","unstructured":"Eismann EA, Lucky AW, Cornwall R. Hand function and quality of life in children with epidermolysis bullosa. Pediatr Dermatol. 2014;31(2):176\u201382.","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"3328_CR13","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/j.1365-2133.2009.09306.x","volume":"161","author":"S Tabolli","year":"2009","unstructured":"Tabolli S, Sampogna F, Di Pietro C, Paradisi A, Uras C, Zotti P, et al. Quality of life in patients with epidermolysis bullosa. Br J Dermatol. 2009;161(4):869\u201377.","journal-title":"Br J Dermatol"},{"issue":"1","key":"3328_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-019-1279-y","volume":"15","author":"AL Bruckner","year":"2020","unstructured":"Bruckner AL, Losow M, Wisk J, Patel N, Reha A, Lagast H, et al. The challenges of living with and managing Epidermolysis Bullosa: insights from patients and caregivers. Orphanet J Rare Dis. 2020;15(1):1.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3328_CR15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13023-021-01815-3","volume":"16","author":"L Garc\u00eda-P\u00e9rez","year":"2021","unstructured":"Garc\u00eda-P\u00e9rez L, Linertov\u00e1 R, Valc\u00e1rcel-Nazco C, Posada M, Gorostiza I, Serrano-Aguilar P. Cost-of-illness studies in rare diseases: a scoping review. Orphanet J Rare Dis. 2021;16(1):178.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3328_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.hlpt.2021.02.002","volume":"10","author":"AR Sequeira","year":"2021","unstructured":"Sequeira AR, Mentzakis E, Archangelidi O, Paolucci F. The economic and health impact of rare diseases: a meta-analysis. Health Policy Technol. 2021;10(1):32\u201344.","journal-title":"Health Policy Technol"},{"issue":"Suppl 1Suppl 1","key":"3328_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10198-016-0783-4","volume":"17","author":"A Angelis","year":"2016","unstructured":"Angelis A, Kanavos P, L\u00f3pez-Bastida J, Linertov\u00e1 R, Oliva-Moreno J, Serrano-Aguilar P, et al. Social\/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe. Eur J Health Econ. 2016;17(Suppl 1Suppl 1):31\u201342.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"3328_CR18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13023-022-02509-0","volume":"17","author":"JA Feinstein","year":"2022","unstructured":"Feinstein JA, Bruckner AL, Chastek B, Anderson A, Roman J. Clinical characteristics, healthcare use, and annual costs among patients with dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2022;17(1):367.","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"3328_CR19","doi-asserted-by":"publisher","first-page":"adv00116","DOI":"10.2340\/00015555-3456","volume":"100","author":"D Flannery","year":"2020","unstructured":"Flannery D, Doyle C, Hickey S, Aherne F, Kennan A. Direct costs of Epidermolysis Bullosa by Disease Severity. Acta Derm Venereol. 2020;100(8):adv00116.","journal-title":"Acta Derm Venereol"},{"key":"3328_CR20","first-page":"146","volume":"35","author":"SF Forghani","year":"2021","unstructured":"Forghani SF, Jahangiri R, Ghasemi F, Shirani R, Bagheri H, Mahmoodi R, et al. Economic Burden of Epidermolysis Bullosa Disease in Iran. Med J Islam Repub Iran. 2021;35:146.","journal-title":"Med J Islam Repub Iran"},{"issue":"1","key":"3328_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13023-021-01811-7","volume":"16","author":"JY Tang","year":"2021","unstructured":"Tang JY, Marinkovich MP, Lucas E, Gorell E, Chiou A, Lu Y, et al. A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2021;16(1):175.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"3328_CR22","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40273-013-0104-z","volume":"31","author":"RJ Hoefman","year":"2013","unstructured":"Hoefman RJ, van Exel J, Brouwer W. How to include informal care in economic evaluations. PharmacoEconomics. 2013;31(12):1105\u201319.","journal-title":"PharmacoEconomics"},{"issue":"9596","key":"3328_CR23","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of Observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453\u20137.","journal-title":"Lancet"},{"issue":"1","key":"3328_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/pde.12391","volume":"32","author":"C Danial","year":"2015","unstructured":"Danial C, Adeduntan R, Gorell ES, Lucky AW, Paller AS, Bruckner A, et al. Prevalence and characterization of pruritus in Epidermolysis Bullosa. Pediatr Dermatol. 2015;32(1):53\u20139.","journal-title":"Pediatr Dermatol"},{"key":"3328_CR25","doi-asserted-by":"crossref","unstructured":"Maseda Pedrero R, Quintana Castanedo L, P\u00e9rez Conde I, Jim\u00e9nez Gonz\u00e1lez M, Esc\u00e1mez Toledano MJ, de Lucas Laguna R. Epidermolysis Bullosa in Spain: Observational Study of a cohort of patients treated in a National Referral Center. Actas Dermosifiliogr (Engl Ed). 2021.","DOI":"10.1016\/j.adengl.2021.07.012"},{"key":"3328_CR26","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford Univeristy; 2015."},{"key":"3328_CR27","unstructured":"Vademecum [Internet]. 2023. https:\/\/www.vademecum.es"},{"key":"3328_CR28","unstructured":"Triantafillou JN, Repkova M, Stiehr K, Carretero K, Emilsson S, Di T, Rastislav P, Lydia S, Ceruzzi B, Cordero F, Mastroyiannakis L, Ferrando T, Mingot M, Ritter K, Vienna J, Leichsenring A. K. Informal care in the long-term care system: European Overview Paper.2010 05\/06\/2023. https:\/\/www.euro.centre.org\/downloads\/detail\/768"},{"key":"3328_CR29","unstructured":"IMSERSO. Servicios Sociales dirigidos a personas mayores en Espa\u00f1a. Madrid: Instituto de Mayores y Servicios Sociales. 2021. https:\/\/imserso.es\/documents\/20123\/2794117\/datos_ssppmmesp2021.pdf\/b17e91ff-d657-df50-2e48-6205d855d803?t=1676835845219"},{"issue":"4","key":"3328_CR30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40273-014-0132-3","volume":"32","author":"M Krol","year":"2014","unstructured":"Krol M, Brouwer W. How to estimate productivity costs in economic evaluations. PharmacoEconomics. 2014;32(4):335\u201344.","journal-title":"PharmacoEconomics"},{"key":"3328_CR31","unstructured":"Wage Structure Survey [Internet]. Instituto Nacional de Estad\u00edstica. 2021. https:\/\/www.ine.es\/dyngs\/INEbase\/en\/operacion.htm?c=Estadistica_C&cid=1254736177025&menu=ultiDatos&idp=1254735976596"},{"issue":"1","key":"3328_CR32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53\u201372.","journal-title":"Health Policy"},{"key":"3328_CR33","doi-asserted-by":"crossref","unstructured":"Villar Hern\u00e1ndez AR, Molero Alonso F, Aguado Mar\u00edn \u00c1J, Posada de la Paz M. Transcultural validation of a Spanish version of the quality of life in Epidermolysis Bullosa Questionnaire. Int J Environ Res Public Health. 2022;19(12).","DOI":"10.3390\/ijerph19127059"},{"issue":"4","key":"3328_CR34","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1017\/S0714980800012484","volume":"19","author":"R H\u00e9bert","year":"2000","unstructured":"H\u00e9bert R, Bravo G, Pr\u00e9ville M, Reliability. Validity and reference values of the Zarit Burden Interview for assessing Informal caregivers of Community-Dwelling older persons with dementia. Can J Aging \/ La Revue Canadienne Du Vieillissement. 2000;19(4):494\u2013507.","journal-title":"Can J Aging \/ La Revue Canadienne Du Vieillissement"},{"issue":"3","key":"3328_CR35","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jval.2016.10.012","volume":"20","author":"JM Ramos-Go\u00f1i","year":"2017","unstructured":"Ramos-Go\u00f1i JM, Oppe M, Slaap B, Busschbach JJ, Stolk E. Quality control process for EQ-5D-5L valuation studies. Value Health. 2017;20(3):466\u201373.","journal-title":"Value Health"},{"issue":"5","key":"3328_CR36","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jval.2017.10.023","volume":"21","author":"JM Ramos-Go\u00f1i","year":"2018","unstructured":"Ramos-Go\u00f1i JM, Craig BM, Oppe M, Ramallo-Fari\u00f1a Y, Pinto-Prades JL, Luo N, et al. Handling Data Quality issues to Estimate the Spanish EQ-5D-5L value set using a hybrid interval Regression Approach. Value Health. 2018;21(5):596\u2013604.","journal-title":"Value Health"},{"issue":"6","key":"3328_CR37","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/j.1365-2133.2009.09347.x","volume":"161","author":"JW Frew","year":"2009","unstructured":"Frew JW, Martin LK, Nijsten T, Murrell DF. Quality of life evaluation in Epidermolysis Bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument. Br J Dermatol. 2009;161(6):1323\u201330.","journal-title":"Br J Dermatol"},{"issue":"3","key":"3328_CR38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.33204\/mucosa.598339","volume":"2","author":"JW Frew","year":"2019","unstructured":"Frew JW. Improving clinical applications of quality of life scores in epidermolysis bullosa: defining clinically significant outcomes in the QOLEB questionnaire. Mucosa. 2019;2(3):68\u201375.","journal-title":"Mucosa"},{"issue":"4","key":"3328_CR39","doi-asserted-by":"publisher","first-page":"442","DOI":"10.2340\/00015555-1758","volume":"94","author":"WY Yuen","year":"2014","unstructured":"Yuen WY, Frew JW, Veerman K, van den Heuvel ER, Murrell DF, Jonkman MF. Health-related quality of life in epidermolysis bullosa: validation of the Dutch QOLEB questionnaire and assessment in the Dutch population. Acta Derm Venereol. 2014;94(4):442\u20137.","journal-title":"Acta Derm Venereol"},{"key":"3328_CR40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1472-6963-9-55","volume":"9","author":"J Lopez-Bastida","year":"2009","unstructured":"Lopez-Bastida J, Oliva-Moreno J, Perestelo-Perez L, Serrano-Aguilar P. The economic costs and health-related quality of life of people with HIV\/AIDS in the Canary Islands, Spain. BMC Health Serv Res. 2009;9:55.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"3328_CR41","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s13023-021-01883-5","volume":"16","author":"J Lopez-Bastida","year":"2021","unstructured":"Lopez-Bastida J, Aranda-Reneo I, Rodr\u00edguez-S\u00e1nchez B, Pe\u00f1a-Longobardo LM, Ye X, Laeis P, et al. Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry. Orphanet J Rare Dis. 2021;16(1):294.","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 1","key":"3328_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10198-016-0780-7","volume":"17","author":"J L\u00f3pez-Bastida","year":"2016","unstructured":"L\u00f3pez-Bastida J, Oliva-Moreno J, Linertov\u00e1 R, Serrano-Aguilar P. Social\/economic costs and health-related quality of life in patients with rare diseases in Europe. Eur J Health Econ. 2016;17(Suppl 1):1\u20135.","journal-title":"Eur J Health Econ"},{"issue":"2","key":"3328_CR43","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/mds.21798","volume":"23","author":"J L\u00f3pez-Bastida","year":"2008","unstructured":"L\u00f3pez-Bastida J, Perestelo-P\u00e9rez L, Mont\u00f3n-Alvarez F, Serrano-Aguilar P. Social economic costs and health-related quality of life in patients with degenerative cerebellar ataxia in Spain. Mov Disord. 2008;23(2):212\u20137.","journal-title":"Mov Disord"},{"issue":"1","key":"3328_CR44","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s13023-022-02419-1","volume":"17","author":"A Angelis","year":"2022","unstructured":"Angelis A, Mellerio JE, Kanavos P. Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe: a costing and health-related quality of life study. Orphanet J Rare Dis. 2022;17(1):346.","journal-title":"Orphanet J Rare Dis"},{"key":"3328_CR45","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1186\/1471-2458-10-675","volume":"10","author":"J Oliva-Moreno","year":"2010","unstructured":"Oliva-Moreno J, Lopez-Bastida J, Worbes-Cerezo M, Serrano-Aguilar P. Health related quality of life of Canary Island citizens. BMC Public Health. 2010;10:675.","journal-title":"BMC Public Health"},{"issue":"12","key":"3328_CR46","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/hec.3952","volume":"28","author":"E S\u00e1nchez-Iriso","year":"2019","unstructured":"S\u00e1nchez-Iriso E, Errea Rodr\u00edguez M, Cabas\u00e9s Hita JM. Valuing health using EQ-5D: the impact of chronic diseases on the stock of health. Health Econ. 2019;28(12):1402\u201317.","journal-title":"Health Econ"},{"key":"3328_CR47","unstructured":"Resoluci\u00f3. sobre el procediment per a l\u2019acc\u00e9s, la prescripci\u00f3, la dispensaci\u00f3, el seguiment i la facturaci\u00f3 dels medicaments t\u00f2pics i productes sanitaris als pacients afectats d\u2019epiderm\u00f2lisi ampul\u00b7lar cong\u00e8nita atesos en r\u00e8gim ambulatori en hospitals del SISCA, (2019)."},{"issue":"1","key":"3328_CR48","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41572-020-0210-0","volume":"6","author":"A Bardhan","year":"2020","unstructured":"Bardhan A, Bruckner-Tuderman L, Chapple ILC, Fine J-D, Harper N, Has C, Magin TM, Marinkovich MP, Marshall JF, McGrath JA, Mellerio JE, Polson R, Heagerty AH. Epidermolysis Bullosa. Nat Reviews Disease Primers. 2020;6(1):78.","journal-title":"Nat Reviews Disease Primers"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03328-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03328-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03328-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T03:36:39Z","timestamp":1727321799000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03328-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3328"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03328-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,23]]},"assertion":[{"value":"5 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The protocol was approved by the hospitals\u2019 ethics committees in accordance with national and regional regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IAR has received grants from Daiichi-Sankyo, Biogen, Lilly and Amryt Pharmaceuticals DAC. JOM has received grants from Biogen, Lilly and Amryt Pharmaceuticals DAC. LMPL has received grants from Daiichi-Sankyo, Biogen and Amryt Pharmaceuticals DAC. JLB has received grants from Daiichi-Sankyo, Biogen, Lilly and Amryt Pharmaceuticals DAC.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The protocol was approved by the hospitals\u2019 ethics committees in accordance with national and regional regulations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"352"}}